SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst intense community debate after pulling its compounded weight-loss pill following regulatory pressure, coinciding with significant buzz around its Super Bowl commercial. Investors are sharply divided, with bulls anticipating a rebound from reduced legal risk, while bears predict further downside due to perceived management missteps and a hit to the company's growth narrative.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending due to record Super Bowl betting volume and its ongoing expansion into prediction markets, sparking community debate over immediate revenue opportunities versus competitive pressures and the evolving regulatory landscape surrounding these platforms.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. It provides online news services where users can select and rank web content. The firm also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit (RDDT) is experiencing a significant stock decline despite reporting strong quarterly earnings, positive guidance, and authorizing a $1 billion share buyback, sparking intense community debate over perceived market manipulation and whether current prices offer a deep value buying opportunity. This drastic price action, contrasting with overall market gains, is fueling discussions about its long-term potential as a unique human-informed data source for AI versus concerns over valuation and user growth metrics.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following its announcement of an expected first-ever adjusted quarterly operating profit and reaching 100 million battery swaps. This news has sparked a fervent debate among investors regarding its true valuation, with bulls anticipating a significant re-rating while bears caution against a temporary rally amid ongoing dilution concerns.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending as investors debate the impact of a recent equity offering, with community focus on a potential partnership with POSCO and upcoming earnings. Sentiment remains split between those optimistic about rising steel prices and domestic demand, and others concerned about management's strategy for long-term shareholder value.

Pagaya Technologies Ltd. engages in the development of AI and data networks for the financial industry. Its product deploys data science, machine learning and AI technology to evaluate the customers' applications in real time. The company was founded by Gal Krubiner, Sanjiv Das, Yahav Yulzari, and Avital Pardo on March 20, 2016 and is headquartered in New York, NY.

Pagaya Technologies Ltd - Ordinary Shares - Class A

Pagaya Technologies Ltd

Pagaya Technologies is actively trending ahead of its Q4 earnings report on February 9, with community speculation about a potential leak and high expectations for a strong beat and optimistic 2026 guidance, driven by its AI-powered credit platform and recent substantial ABS and forward flow agreements. Despite these strong fundamentals and expanding partnerships, the stock remains a hotly debated topic, with many viewing it as significantly undervalued while others express frustration over persistent market volatility and broader fintech sector pressures.

WorldFinancial

WLFI is trending due to a congressional probe into a significant foreign investment and its pursuit of a US banking license for its USD1 stablecoin, sparking intense community debate. Investors are polarized between those who view it as a politically-linked "scam" and others who see long-term potential in its Real-World Asset (RWA) tokenization and "future of finance" aspirations.

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending after announcing a $250 million financing amendment extending its capital runway through 2028, triggering widespread community speculation for a potential short squeeze, though some caution against its history of volatility and concerns over dilution.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the Platform and Devices segments. The Platform segment includes digital advertising and related services including the demand-side platform and content distribution services such as subscription and transaction revenue shares, media and entertainment promotional spending, the sale of premium subscriptions, and the sale of branded channel buttons on remote controls. The Devices segment is involved in the sale of streaming players, audio products, smart home products, and accessories that are sold through retailers and distributors, as well as directly to customers through the company’s website. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

A flurry of analyst upgrades, citing Roku's strengthening advertising platform and strategic partnerships, is driving conversation, though the stock's volatility has fueled community debate over short influence ahead of its impending financial results. Investors are keenly watching for a breakout, propelled by Roku's expansive user base and growing dominance in the Connected TV ad market.

Pinterest, Inc. engages in the operation of a pinboard-style photo-sharing website. It allows users to create and manage theme-based image collections such as events, interests, and hobbies. The company was founded by Benjamin Silbermann, Paul C. Sciarra, and Evan Sharp in October 2008 and is headquartered in San Francisco, CA.

Pinterest Inc - Ordinary Shares - Class A

Pinterest Inc

Pinterest is trending amid a strategic workforce reduction focusing on AI initiatives, fueling community discussion around its perceived undervaluation and strong balance sheet, especially as rumors circulate about potential acquisition interest from major players like OpenAI and Reddit ahead of its highly anticipated earnings report.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Savant Capital LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Savant Capital LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 346.6% in the 3rd quarter, according to its most recent Form 13F filing with the...

Thrivent Financial for Lutherans Sells 1,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Thrivent Financial for Lutherans reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 20.8% in the 3rd quarter, according to its most recent filing with the SEC. The...

Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Sunday...

Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Murphy Pohlad Asset Management LLC

Murphy Pohlad Asset Management LLC raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 117.3% during the third quarter, according to the company in its most recent...

Prime Capital Investment Advisors LLC Buys 11,835 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Prime Capital Investment Advisors LLC boosted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 1,852.1% during the 3rd quarter, according to its most recent 13F filing with...

Bronte Capital Management Pty Ltd. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Bronte Capital Management Pty Ltd. lessened its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.0% in the third quarter, according to the company in its most recent 13F...

NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study

Novo Nordisk reports that CagriSema beats semaglutide at HbA1c reduction and weight loss in a 68-week phase III diabetes study, with no weight-loss plateau.

Here's Why Gilead Sciences Stock Surged 21% in a Month 

GILD shares gain traction post Jan. 20 after NEJM data show Trodelvy plus Keytruda cut progression risk 35% in first-line PD-L1+ metastatic TNBC, signaling a new care standard.

<ul class="summary-bullets"><li>Several Wall Street firms raised price targets on Regeneron after its Q4 results.</li><li>Q4 revenue and non-GAAP earnings both exceeded Wall Street estimates.</li><li>Eylea HD sales rose sharply, while sales of the original Eylea fell.</li></ul>Regeneron Pharmaceuticals shares fell 0.4% in premarket trading on Monday as investors focused on weakness in the core Eylea business, even after multiple Wall Street firms raised their price targets following the company’s fourth-quarter (Q4) earnings report.<h2 class="st-heading-2">Analyst Calls Lift Premarket Tone</h2>Wells Fargo raised its price target on Regeneron to $800 from $745, implying about 8% upside from Friday’s close of $741.45, and maintained an ‘Equal Weight’ rating. The firm said management’s commentary on a potential extension of Dupixent’s intellectual property was encouraging. Dupixent is the company’s eczema and asthma treatment. Wells Fargo also noted upside to 2026 estimates, while adding that the stock still lacks near-term catalysts.Morgan Stanley issued a slight raise, increasing its price target to $769 from $768, pointing to a roughly 4% upside, and maintained an ‘Equal Weight’ rating. The brokerage called Q4 “uneventful” and expects Phase 3 melanoma data to be the next catalyst.Raymond James was more bullish, lifting its price target to $870 from $820, marking a 17% upside, while maintaining an 'Outperform' rating. The analyst firm said investors should focus on what they see beyond the near-term noise, reasoning that Eylea HD label enhancements should position the franchise to gain market share, and 2026 could be a key pipeline year with multiple late-stage readouts.<h2 class="st-heading-2">Eylea HD Growth Lifts Q4 Print</h2>The analyst revisions followed Regeneron’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/regn-stock-slips-regeneron-earnings-q4-eylea-hd-revenue/cmySjWfR4S5">Q4 earnings</a> report on Friday, which exceeded expectations despite mixed trends across its product portfolio.Revenue rose 3% year over year to $3.88 billion, topping Wall Street forecasts of $3.78 billion, according to Fiscal.ai. Non-GAAP earnings slipped 5% to $11.44 per share, but still beat analyst estimates of $10.74.Sales of Eylea HD, the company’s eye injection for retinal diseases, climbed 66% in the quarter as demand increased, though gains were partly offset by lower pricing. At the same time, sales of the original Eylea formulation fell 52%, reflecting competitive pressure, patient shifts to the high-dose version, and increased use of lower-cost alternatives. Collaboration revenue with Sanofi jumped 35%, driven primarily by stronger sales of Dupixent.Looking ahead, Regeneron forecasts non-GAAP R&amp;D spending of $5.90 billion to $6.10 billion for full-year 2026, up from $5.15 billion in fiscal 2025. The company said it now has around 45 product candidates in clinical development.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for Regeneron was ‘bearish’ amid ‘high’ message volume.<a href="https://stocktwits.com/symbol/REGN">Regeneron’s stock</a> has risen 9% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Regeneron Pharmaceuticals company logo is displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Regeneron Stock Slips Premarket Even After Wall Street Lifts Targets On Strong Q4 — What’s Weighing On The Stock?

Regeneron Stock - Analysts said near-term catalysts remain limited, with Phase 3 melanoma data as the next key event to watch.

Equity

Analysts said near-term catalysts remain limited, with Phase 3 melanoma data as the next key event to watch.

Best Pharmaceutical Stocks To Watch Today - February 1st

Eli Lilly and Company, Abbott Laboratories, AbbVie, Pfizer, Gilead Sciences, Regeneron Pharmaceuticals, and Bristol Myers Squibb are the seven Pharmaceutical stocks to watch today, according to...

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Regeneron Pharmaceuticals, Inc.

Up 5%

Down 5%

Markets are hovering near key levels, making the next 5% move especially important for sentiment. A breakout higher could reinforce the bull case, while a 5% drop may signal rising risk and tighter conditions. Which comes first?

What will be the S&amp;P 500’s next 5% move?

Stocktwits

What will be the S&P 500’s next 5% move?

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	$9.15	--	--	N/A
Q4 '25	$10.74	$11.44	6.56%	BEAT
Q3 '25	$9.65	$11.83	22.53%	BEAT
Q2 '25	$8.43	$12.89	52.89%	BEAT
Q1 '25	$8.62	$8.22	-4.66%	MISSED

REGN
Regeneron Pharmaceuticals, Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q4 '25

Historical Earnings

Latest REGN News

REGNRegeneron Pharmaceuticals, Inc.